Other formats:
BibTeX
LaTeX
RIS
@article{1807837,
author = {Curylová, Lucie and Ramos, Helena and Saraiva, Lucília and Škoda, Jan},
article_number = {January},
doi = {http://dx.doi.org/10.1016/j.canlet.2021.10.037},
keywords = {p53; Sarcoma; Mesenchymal stem cells; Cancer stem cells; p53-targeted therapy},
language = {eng},
issn = {0304-3835},
journal = {Cancer letters},
title = {Noncanonical roles of p53 in cancer stemness and their implications in sarcomas},
url = {https://www.sciencedirect.com/science/article/pii/S030438352100553X?via%3Dihub},
volume = {525},
year = {2022}
}
TY - JOUR
ID - 1807837
AU - Curylová, Lucie - Ramos, Helena - Saraiva, Lucília - Škoda, Jan
PY - 2022
TI - Noncanonical roles of p53 in cancer stemness and their implications in sarcomas
JF - Cancer letters
VL - 525
IS - January
SP - 131-145
EP - 131-145
PB - Elsevier Ireland Ltd
SN - 03043835
KW - p53
KW - Sarcoma
KW - Mesenchymal stem cells
KW - Cancer stem cells
KW - p53-targeted therapy
UR - https://www.sciencedirect.com/science/article/pii/S030438352100553X?via%3Dihub
N2 - Impairment of the prominent tumor suppressor p53, well known for its canonical role as the "guardian of the genome", is found in almost half of human cancers. More recently, p53 has been suggested to be a crucial regulator of stemness, orchestrating the differentiation of embryonal and adult stem cells, suppressing reprogramming into induced pluripotent stem cells, or inhibiting cancer stemness (i.e., cancer stem cells, CSCs), which underlies the development of therapy-resistant tumors. This review addresses these noncanonical roles of p53 and their implications in sarcoma initiation and progression. Indeed, dysregulation of p53 family proteins is a common event in sarcomas and is associated with poor survival. Additionally, emerging studies have demonstrated that loss of wild-type p53 activity hinders the terminal differentiation of mesenchymal stem cells and leads to the development of aggressive sarcomas. This review summarizes recent findings on the roles of aberrant p53 in sarcoma development and stemness and further describes therapeutic approaches to restore normal p53 activity as a promising anti-CSC strategy to treat refractory sarcomas.
ER -
CURYLOVÁ, Lucie, Helena RAMOS, Lucília SARAIVA and Jan ŠKODA. Noncanonical roles of p53 in cancer stemness and their implications in sarcomas. \textit{Cancer letters}. Elsevier Ireland Ltd, 2022, vol.~525, January, p.~131-145. ISSN~0304-3835. Available from: https://dx.doi.org/10.1016/j.canlet.2021.10.037.
|
